Sunday 18 October 2026
Export GALT’s income statement to Excel — free account
Galectin Therapeutics Inc.
GALT Healthcare Biotechnology
In the quarter to June 2026, EPS fell 16.7%, free cash flow grew 63.1% and total debt fell 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.62
0.09
−2.43%
Follow GALT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
33.96% | 26.51% | 21.41% | 21.69% | |
| (178.99%) | (167.30%) | (209.09%) | (184.22%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
30.26% | (271.56%) | (315.31%) | 20.46% | |
Free Cash Flow per Share |
(0.48) | (0.37) | (0.30) | (0.24) | |
Free Cash Flow |
(30.62) | (23.87) | (20.05) | (15.89) | |
| Other line items | |||||
Cash ROIC |
137.32% | (94.52%) | (102.39%) | 83.96% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(4.10) | (2.74) | (2.15) | (2.02) | |
Operating CF/Net income |
0.82 | 0.77 | 0.76 | 0.57 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.48) | (0.37) | (0.30) | (0.24) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates